Stoke Therapeutics reports Q3 2026 results, zero dropouts in EMPEROR trial and cash runway into early 2028
Stoke Therapeutics announced its third‑quarter 2026 update, noting that the EMPEROR Phase 3 trial for zorevunersen enrolled 162 patients with no treatment discontinuations. About 110 patients have completed the Week 28 primary endpoint and roughly 20 have reached Week 52, all continuing into the open‑label extension. The company ended the quarter with $358.8 million in cash and expects that funding to support operations into early 2028 while it plans to submit an NDA for zorevunersen in the first half of 2027. Net loss for the quarter was $73.6 million.
Why it matters
The cash position gives Stoke runway to continue development and commercial preparation through early 2028, reducing financing risk. The NDA timeline signals a potential U.S. launch in 2028 if the trial meets its endpoints, which could create a new revenue stream for the company.
Key facts
- 1The EMPEROR trial enrolled 162 patients, exceeding the original target of 150. investing.com
- 2Zero patients discontinued treatment in the EMPEROR trial. investing.com
- 3Approximately 110 patients have completed the Week 28 primary endpoint measurement. investing.com
- 4About 20 patients have reached the Week 52 secondary endpoint and all continued into the open‑label extension. investing.com
- 5Stoke ended Q3 2026 with $358.8 million in cash, cash equivalents and marketable securities. investing.com
- 6Net loss for the three months ended Sept. 30 was $73.6 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.